Follow the link below to watch the Key Opinion Leader (KOL) Perspectives Webinar on the Pathophysiology and Treatment of IgA Nephropathy in Clinical Practice.
The webinar featured a presentation from KOL Richard Lafayette, M.D., F.A.C.P., Stanford Healthcare, who discussed the pathophysiology of IgA nephropathy, the connection between the gut and kidney, and how Calliditas’ lead clinical candidate, Nefecon, might be used in clinical practice, should it be approved. Calliditas CEO, Renee Aguiar-Lucander, and CMO, Dr Richard Phillipson, also gave a brief corporate update and discussed data from the global Phase 3 NefIgArd trial.
This was followed by a Q&A session with all three presenters.
About Dr Richard Lafayette
Dr. Lafayette is Professor of Medicine (Nephrology) at the Stanford University Medical Center. He is the founder and director of the Stanford Glomerular Disease Center and its fellowship training program. He has a longstanding interest in glomerular disease with a focus on IgA nephropathy. This interest has led to many evaluations and some elucidation of the pathogenesis of IgA nephritis and leadership in many clinical trials. He has more than 25 years of clinical experience and has more than 125 publications including 75 peer reviewed papers. He remains passionate in efforts to discover safer and more effective treatments for patients.